Humana Inc. (HUM) Balance Sheet

The balance sheet is expanding at an accelerating pace, with total assets rising from $50.1B in 2024Q2 to $57.2B in 2026Q2, a 14.2% increase. This growth is primarily funded by a corresponding increase in total liabilities, which grew from $33.4B to $37.9B over the same period, reflecting higher claims reserves. The equity base has also strengthened, increasing from $16.7B to $19.2B, indicating retained earnings are supporting capital accumulation. However, the rapid growth in liabilities, particularly claims payable, suggests that the company is underwriting more business, which may strain future capital if loss ratios deteriorate.

The claims and loss reserves have grown from $27.6B in 2025Q2 to $35.4B in 2026Q2, a 28.3% increase, which is nearly double the asset growth rate. This suggests that Humana is setting aside more funds for future claims, possibly due to higher medical cost trends or changes in membership mix. The reserve build-up may be prudent, but it also implies that the company expects higher payouts, which could pressure future profitability. Investors should monitor whether these reserves are sufficient, as any adverse development could impact the balance sheet.

Humana's equity base has grown steadily, from $16.4B in 2024Q4 to $19.2B in 2026Q2, reflecting retained earnings and modest capital returns. The equity-to-assets ratio has remained relatively stable around 33-34%, indicating a consistent capital structure. However, the growth in equity is slower than the growth in liabilities, which may indicate that the company is leveraging up to fund expansion. The capital position appears adequate, but the thin underwriting margins and reliance on reserve releases suggest that the quality of capital may be a concern.

The balance sheet reports negligible invested assets and no cash balance, which is unusual for an insurance carrier. This may indicate that the data provided is incomplete or that Humana's investment portfolio is held in subsidiaries not consolidated in this snapshot. Given the lack of visibility into liquid assets, it is difficult to assess the company's ability to meet unexpected claims. Investors should seek additional disclosures on the investment portfolio and cash positions to evaluate liquidity risk.

The increase in claims liabilities is consistent with the revenue growth reported in the income statement, indicating that Humana is writing more premiums. However, without explicit unearned premium figures, it is difficult to gauge the sustainability of this growth. The company's exposure to Medicare Advantage, which is subject to regulatory reimbursement changes, adds uncertainty to future premium levels. Investors should monitor membership trends and regulatory developments to assess forward visibility.